Lunsford L Dade, Niranjan Ajay, Flickinger John C, Maitz Ann, Kondziolka Douglas
Department of Neurological Surgery and Radiation Oncology, The University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA.
J Neurosurg. 2005 Jan;102 Suppl:195-9.
Management options for vestibular schwannomas (VSs) have greatly expanded since the introduction of stereotactic radiosurgery. Optimal outcomes reflect long-term tumor control, preservation of cranial nerve function, and retention of quality of life. The authors review their 15-year experience.
Between 1987 and 2002, some 829 patients with VSs underwent gamma knife surgery (GKS). Dose selection, imaging, and dose planning techniques evolved between 1987 and 1992 but thereafter remained stable for 10 years. The average tumor volume was 2.5 cm3. The median margin dose to the tumor was 13 Gy (range 10-20 Gy). No patient sustained significant perioperative morbidity. The average duration of hospital stay was less than 1 day. Unchanged hearing preservation was possible in 50 to 77% of patients (up to 90% in those with intracanalicular tumors). Facial neuropathy risks were reduced to less than 1%. Trigeminal symptoms were detected in less than 3% of patients whose tumors reached the level of the trigeminal nerve. Tumor control rates at 10 years were 97% (no additional treatment needed).
Superior imaging, multiple isocenter volumetric conformal dose planning, and optimal precision and dose delivery contributed to the long-term success of GKS, including in those patients in whom initial microsurgery had failed. Gamma knife surgery provides a low risk, minimally invasive treatment option for patients with newly diagnosed or residual VS. Cranial nerve preservation and quality of life maintenance are possible in long-term follow up.
自立体定向放射外科引入以来,前庭神经鞘瘤(VS)的治疗选择有了极大扩展。最佳治疗效果体现在长期的肿瘤控制、保留颅神经功能以及维持生活质量。作者回顾了他们15年的经验。
1987年至2002年间,约829例VS患者接受了伽玛刀手术(GKS)。1987年至1992年间剂量选择、成像及剂量规划技术不断发展,但此后10年保持稳定。肿瘤平均体积为2.5立方厘米。肿瘤的中位边缘剂量为13 Gy(范围10 - 20 Gy)。无患者出现显著的围手术期并发症。平均住院时间少于1天。50%至77%的患者听力得以保留(内听道内肿瘤患者高达90%)。面神经病变风险降至1%以下。肿瘤累及三叉神经水平的患者中,三叉神经症状的发生率低于3%。10年时的肿瘤控制率为97%(无需额外治疗)。
先进的成像技术、多等中心容积适形剂量规划以及最佳的精度和剂量投送促成了GKS的长期成功,包括那些初次显微手术失败的患者。伽玛刀手术为新诊断或残留VS患者提供了一种低风险、微创的治疗选择。长期随访中可实现颅神经保留及生活质量维持。